Company news
Livzon Pharmaceutical Group, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Interim Report 2023
August 22, 2023
Interim Report 2022
August 9, 2022
2022 First quarterly report
April 21, 2022
Livzon Pharmaceutical was recognized as the National Enterprise Technology Center with High Scores
April 20, 2022
A Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed and manufactured by Livzon has shown good protective effects against the Omicron variant in a phase III clinical booster trial
April 20, 2022
Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) approved by China NMPA.
April 20, 2022
V-01 as a Sequential Booster Can Produce Good Protection against Omicron ---- Latest Phase III Data of COVID-19 Vaccine by Livzon Pharma
February 18, 2022
Announcement on progress of the reorganization
May 12, 2021
Voluntary announcement launch of futures hedging activities by controlling subsidiaries
May 6, 2021
Cancellation of the repurchased h shares
May 6, 2021
Voluntary announcement update announcement on acquisition of 40.00% equity interest in tianjin tongrentang
April 27, 2021
Livzon Pharmaceutical Group: Proposed company's provision of financing guarantees to controlling subsidiary livzon mab
April 15, 2021
Livzon Pharmaceutical Group: Proposed adoption of the first phase ownership scheme (draft) and its administrative measures under the medium to long-term business partner share ownership scheme
April 14, 2021
Livzon Pharmaceutical Group: Connected transaction in relation to grant of subscription to connected persons pursuant to the proposed first phase ownership scheme
April 8, 2021